比较莫西沙星、左氧氟沙星和加替沙星对肺炎链球菌的突变预防浓度。
Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
机构信息
Department of Pathology, Hershey Medical Center, P.O. Box 850, Hershey, PA 17033, USA.
出版信息
Antimicrob Agents Chemother. 2010 Feb;54(2):673-7. doi: 10.1128/AAC.01353-09. Epub 2009 Dec 14.
Abstract
We tested the propensity of three quinolones to select for resistant Streptococcus pneumoniae mutants by determining the mutant prevention concentration (MPC) against 100 clinical strains, some of which harbored mutations in type II topoisomerases. Compared with levofloxacin and gemifloxacin, moxifloxacin had the lowest number of strains with MPCs above the susceptibility breakpoint (P<0.001), thus representing a lower selective pressure for proliferation of resistant mutants. Only moxifloxacin gave a 50% MPC (MPC50) value (1 microg/ml) within the susceptible range.
摘要
我们通过测定 100 株临床分离株的突变预防浓度（MPC）来检测三种喹诺酮类药物选择耐药肺炎链球菌突变株的倾向性，这些分离株中有些含有 II 型拓扑异构酶突变。与左氧氟沙星和加替沙星相比，莫西沙星有更高比例的菌株 MPC 值高于药敏折点（P<0.001），这表明其对耐药突变株的选择压力更低。只有莫西沙星在敏感范围内（MPC50 值为 1μg/ml）得到 50% MPC 值。
相似文献
1
Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.比较莫西沙星、左氧氟沙星和加替沙星对肺炎链球菌的突变预防浓度。
Antimicrob Agents Chemother. 2010 Feb;54(2):673-7. doi: 10.1128/AAC.01353-09. Epub 2009 Dec 14.
2
Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.肺炎链球菌对氟喹诺酮类药物的耐药性：浓度-时间曲线下面积与最低抑菌浓度比值以及加替沙星、吉米沙星、左氧氟沙星和莫西沙星导致的耐药性发展情况
Antimicrob Agents Chemother. 2007 Apr;51(4):1315-20. doi: 10.1128/AAC.00646-06. Epub 2007 Feb 12.
3
Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.新型喹诺酮类药物DW - 224a与其他八种药物的抗肺炎球菌活性比较。
Antimicrob Agents Chemother. 2006 Jun;50(6):2064-71. doi: 10.1128/AAC.00153-06.
4
In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV.加替沙星、吉米沙星、莫西沙星和左氧氟沙星对含有DNA旋转酶和拓扑异构酶IV特定突变的肺炎链球菌的体外药效学活性。
Diagn Microbiol Infect Dis. 2003 Dec;47(4):587-93. doi: 10.1016/s0732-8893(03)00152-4.
5
Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.在体外药效学模型中，突变预防浓度靶向的莫西沙星和左氧氟沙星对肺炎链球菌的活性。
Antimicrob Agents Chemother. 2003 Aug;47(8):2606-14. doi: 10.1128/AAC.47.8.2606-2614.2003.
6
In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.在脓毒症小鼠模型中，采用全或无死亡率终点指标测定吉米沙星、莫西沙星和左氧氟沙星对携带gyrA和parC点突变肺炎球菌的体内活性。
Int J Antimicrob Agents. 2005 Feb;25(2):163-7. doi: 10.1016/j.ijantimicag.2004.08.017.
7
The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.金黄色葡萄球菌和肺炎链球菌对不同氟喹诺酮类药物的耐药性选择及致突变性
Clin Microbiol Infect. 2005 Sep;11(9):750-8. doi: 10.1111/j.1469-0691.2005.01211.x.
8
Relative potential for selection of quinolone-resistance-determining-region mutations in Streptococcus pneumoniae by gemifloxacin, gatifloxacin and moxifloxacin.吉米沙星、加替沙星和莫西沙星对肺炎链球菌喹诺酮耐药决定区突变的相对选择潜力
J Chemother. 2006 Aug;18(4):373-8. doi: 10.1179/joc.2006.18.4.373.
9
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.11种抗肺炎球菌抗生素通过多步和单步方法选择耐药性的能力。
Antimicrob Agents Chemother. 2007 Nov;51(11):4196-201. doi: 10.1128/AAC.00827-07. Epub 2007 Sep 17.
10
In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.莫西沙星与左氧氟沙星对4株肺炎链球菌（1株野生型、2株parC第一步突变株和1株泵突变株）的体外药效学研究
Diagn Microbiol Infect Dis. 2008 Feb;60(2):155-61. doi: 10.1016/j.diagmicrobio.2007.08.005. Epub 2007 Oct 29.
引用本文的文献
1
The activity of danofloxacin plus ceftiofur combination: implications for antimicrobial efficacy and resistance prevention.达氟沙星与头孢噻呋联合用药的活性：对抗菌疗效和耐药性预防的意义
Vet Res Forum. 2022 Jun;13(2):149-153. doi: 10.30466/vrf.2020.113272.2696. Epub 2022 Jun 15.
2
Design and virtual screening of novel fluoroquinolone analogs as effective mutant DNA GyrA inhibitors against urinary tract infection-causing fluoroquinolone resistant .新型氟喹诺酮类似物作为针对引起尿路感染的氟喹诺酮耐药性的有效突变型DNA促旋酶A抑制剂的设计与虚拟筛选
RSC Adv. 2018 Jun 29;8(42):23629-23647. doi: 10.1039/c8ra01854e. eCollection 2018 Jun 27.
3
In vitro susceptibility of four antimicrobials against Riemerella anatipestifer isolates: a comparison of minimum inhibitory concentrations and mutant prevention concentrations for ceftiofur, cefquinome, florfenicol, and tilmicosin.四种抗菌药物对鸭疫里默氏菌分离株的体外敏感性：头孢噻呋、头孢喹肟、氟苯尼考和替米考星的最低抑菌浓度与突变预防浓度比较
BMC Vet Res. 2016 Nov 9;12(1):250. doi: 10.1186/s12917-016-0796-3.
4
Molecular Investigation of Quinolone Resistance of Quinolone Resistance-Determining Region in Streptococcus pneumoniae Strains Isolated from Iran Using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism Method.采用聚合酶链反应-限制性片段长度多态性方法对从伊朗分离的肺炎链球菌菌株喹诺酮耐药决定区喹诺酮耐药性进行分子研究。
Osong Public Health Res Perspect. 2014 Oct;5(5):245-50. doi: 10.1016/j.phrp.2014.08.010. Epub 2014 Sep 6.
5
Antibiotic activity against naive and induced Streptococcus pneumoniae biofilms in an in vitro pharmacodynamic model.在体外药效学模型中，抗生素对天然和诱导性肺炎链球菌生物膜的活性。
Antimicrob Agents Chemother. 2014;58(3):1348-58. doi: 10.1128/AAC.01858-13. Epub 2013 Dec 16.
6
"Ten Commandments" for the Appropriate use of Antibiotics by the Practicing Physician in an Outpatient Setting.门诊执业医师合理使用抗生素的“十诫”
Front Microbiol. 2011 Nov 24;2:230. doi: 10.3389/fmicb.2011.00230. eCollection 2011.
7
Mutant prevention concentrations of four carbapenems against gram-negative rods.四种碳青霉烯类药物对革兰氏阴性菌的突变预防浓度。
Antimicrob Agents Chemother. 2010 Jun;54(6):2692-5. doi: 10.1128/AAC.00033-10. Epub 2010 Mar 22.
本文引用的文献
1
Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain.西班牙7价结合疫苗接种后耐氟喹诺酮肺炎链球菌的变化
Emerg Infect Dis. 2009 Jun;15(6):905-11. doi: 10.3201/eid1506.080684.
2
In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.加雷沙星对具有明确耐药机制的肺炎链球菌突变株的体外活性。
Antimicrob Agents Chemother. 2009 Aug;53(8):3572-5. doi: 10.1128/AAC.00176-09. Epub 2009 May 18.
3
Effect of protein binding on the pharmacological activity of highly bound antibiotics.蛋白质结合对高结合率抗生素药理活性的影响。
Antimicrob Agents Chemother. 2008 Nov;52(11):3994-4000. doi: 10.1128/AAC.00427-08. Epub 2008 Sep 8.
4
Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.基于氟喹诺酮类药物的突变预防浓度进行药效学评估，以防止肺炎链球菌耐药突变体的出现。
Antimicrob Agents Chemother. 2007 Nov;51(11):3810-5. doi: 10.1128/AAC.01372-06. Epub 2007 Jul 30.
5
Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.在体外动态模型中，用暴露于达托霉素和万古霉素的金黄色葡萄球菌检验突变选择窗假说。
J Antimicrob Chemother. 2006 Dec;58(6):1185-92. doi: 10.1093/jac/dkl387. Epub 2006 Oct 5.
6
Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones.两种方法在测定各种氟喹诺酮类药物对肺炎链球菌杀菌效果中的应用。
J Chemother. 2006 Aug;18(4):366-72. doi: 10.1179/joc.2006.18.4.366.
7
Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.新型喹诺酮类药物DW - 224a与其他八种药物的抗肺炎球菌活性比较。
Antimicrob Agents Chemother. 2006 Jun;50(6):2064-71. doi: 10.1128/AAC.00153-06.
8
Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa.环丙沙星和左氧氟沙星对铜绿假单胞菌的突变预防浓度。
Int J Antimicrob Agents. 2006 Feb;27(2):120-4. doi: 10.1016/j.ijantimicag.2005.10.005. Epub 2006 Jan 19.
9
Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.ABT-492、左氧氟沙星、莫西沙星和加替沙星对三种常见呼吸道病原体的突变预防浓度。
Antimicrob Agents Chemother. 2005 Apr;49(4):1633-5. doi: 10.1128/AAC.49.4.1633-1635.2005.
10
Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.野生型、外排阳性或含有ParC或GyrA突变的肺炎链球菌分离株的单步氟喹诺酮耐药突变体的突变预防浓度。
Antimicrob Agents Chemother. 2004 Oct;48(10):3954-8. doi: 10.1128/AAC.48.10.3954-3958.2004.
Zotero 插件